EUVIMEDEUVIMED entdecken
Crossref

When Are Pregnant Patients Receiving Tranexamic Acid during Delivery Hospitalization in the United States?

Julia Whitley iD, Seyedeh A Miran, Phillip Ma, George Saade, Ian Roberts, Homa K Ahmadzia iD

American Journal of Perinatology · 01.02.2025 · 42 (03) · 327-333

DOI: 10.1055/a-2353-0832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.02.2025. Verfasst von Julia Whitley und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Maternal-Fetal Medicine and Ultrasound, Department of Obstetrics and Gynecology, Washington University School of Medicine in St. Louis, S…. Hauptthemen laut MEDLINE: Tranexamic Acid, Antifibrinolytic Agents, Postpartum Hemorrhage, Delivery, Obstetric. Die Arbeit nennt 18 Literaturangaben. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The World Health Organization recommends tranexamic acid (TXA) in the management of postpartum hemorrhage (PPH). However, the role of TXA in PPH prevention and the optimal timing of TXA administration remain unknown. Our objective was to describe the timing of TXA administration, differences in timing of TXA administration by mode of delivery, and current trends in TXA administration in the United States. Study Design We conducted a descriptive study of trends in TXA administration using the Cerner Real-World Database. We identified 1,544,712 deliveries occurring at greater than 24 weeks' gestation from January 1, 2016, to February 21, 2023. Demographic data were collected including gestational age, mode of delivery, and comorbidities. The timing of TXA administration and differences in TXA timing by mode of delivery were also collected.

Results

In our cohort, 21,433 patients (1.39%) received TXA. The majority of patients who received TXA were between ages 25 and 34 years old (55.3%), White (60.7%), and delivered between 37 and 416/7 weeks (81.4%). The TXA group had a higher prevalence of medical comorbidities including obesity (32.9 vs. 19.0%, p < 0.00001), preeclampsia (19.6 vs. 6.81%, p < 0.00001), and pregestational diabetes (3.27 vs. 1.36%, p < 0.00001). Among women who received TXA, 15.4% received it within 3 hours before delivery. Among patients who received TXA after delivery, 23.6% received TXA within 3 hours after delivery, whereas 35.7% received TXA between 10 and 24 hours after delivery. A total of 80.4% of patients who received TXA before delivery had a cesarean delivery.

Conclusion

While TXA is most commonly administered after delivery, many patients are receiving TXA prior to delivery in the United States without clear evidence to guide the timing of administration. A randomized trial is urgently needed to determine the safety and efficacy of TXA when administered prior to delivery. Key Points

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidAntifibrinolytic AgentsPostpartum HemorrhageDelivery, ObstetricHumansFemalePregnancyAdultUnited StatesCesarean SectionGestational AgeHospitalizationRetrospective StudiesYoung AdultTime Factors

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Division of Maternal-Fetal Medicine and Ultrasound, Department of Obstetrics and Gynecology, Washington University School of Medicine in St. Louis, St. Louis, Missouri.
  • Department of Clinical Research and Leadership, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
  • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, Virginia.
  • Clinical Trials Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
  • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Health System, Falls Church, Virginia.

ORCID-Profile: Julia Whitley, Homa K Ahmadzia

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Whitley, J., Miran, S. A., Ma, P., Saade, G., Roberts, I., & Ahmadzia, H. K. (2025). When Are Pregnant Patients Receiving Tranexamic Acid during Delivery Hospitalization in the United States?. American Journal of Perinatology, 42(03), 327-333. https://doi.org/10.1055/a-2353-0832

Vancouver

Whitley J, Miran SA, Ma P, Saade G, Roberts I, Ahmadzia HK. When Are Pregnant Patients Receiving Tranexamic Acid during Delivery Hospitalization in the United States?. American Journal of Perinatology. 2025;42(03):327-333. doi:10.1055/a-2353-0832

BibTeX
@article{Whitley2025,
  author = {Whitley, Julia and Miran, Seyedeh A and Ma, Phillip and Saade, George and Roberts, Ian and Ahmadzia, Homa K},
  title = {When Are Pregnant Patients Receiving Tranexamic Acid during Delivery Hospitalization in the United States?},
  journal = {American Journal of Perinatology},
  year = {2025},
  volume = {42},
  number = {03},
  pages = {327--333},
  doi = {10.1055/a-2353-0832}
}
Kostenlos starten →